Results 11 to 20 of about 138,640 (301)
The Oncologist, 2001 Abstract This article reviews highlights in the field of hematologic malignancies presented at the 2001 annual meeting of the American Society of Clinical Oncology. Targeted therapies continue to proceed from the laboratory to the clinic.
M, Petryk, M L, Grossbard
+6 more sources
Immunotherapy in Hematologic Malignancies [PDF]
Current Oncology, 2020 The management of hematologic malignancies has traditionally relied on chemotherapy regimens, many of which are still in use today. However, with advancements in the knowledge of tumour pathophysiology, therapies are continually evolving. Monoclonal antibodies against specific targets on tumour cells are now widely used to treat hematologic ...
Kansara, R.R., Speziali, C.
openaire +2 more sources
BMC Medicine, 2021 Background Although there are many clinical and molecular biomarkers in acute myeloid leukemia (AML), the novel and reliable biomarkers are still required to predict the overall survival at the time of disease diagnosis.
Jinghan Wang +10 more
doaj +1 more source
Haematologica, 2023 Chemoimmunotherapy followed by consolidative high-dose therapy with autologous stem cell rescue was a standard upfront treatment for fit patients with mantle cell lymphoma (MCL) in first remission; however, treatment paradigms are evolving in the era of
Zachary D. Epstein-Peterson +23 more
doaj +1 more source
“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy
Frontiers in Oncology, 2023 BackgroundThe first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines of therapy.
Nausheen Ahmed +14 more
doaj +1 more source
Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis
Haematologica, 2023 Over the past two decades, there have been significant advances in the treatment of multiple myeloma which has led to an improvement in overall survival.1,2 However, a notable proportion of patients continue to experience early mortality (EM), defined ...
John X. Wei +11 more
doaj +1 more source
A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia [PDF]
, 2016 We report the findings from a patient who presented with a concurrent mediastinal germ cell tumor (GCT) and acute myeloid leukemia (AML). Bone marrow pathology was consistent with a diagnosis of acute megakaryoblastic leukemia (AML M7), and biopsy of an ...
Demeter, Ryan T +12 more
core +2 more sources
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors [PDF]
, 2009 PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists.
Agarwal, Shruti +9 more
core +1 more source
Determinants of hospital death in haematological cancers: findings from a qualitative study [PDF]
, 2017 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. Objectives: Current UK health policy promotes enabling people to die in a place they choose, which for most is home.
Garry, Anne +7 more
core +2 more sources
Frontiers in Immunology, 2022 BackgroundNatural killer (NK) cells play a vital role in early immune reconstitution following allogeneic hematopoietic stem cell transplantation (HSCT).MethodsA literature search was performed on PubMed, Cochrane, and Clinical trials.gov through April ...
Muhammad Umair Mushtaq +16 more
doaj +1 more source